The Journal of Korean Medicine Ophthalmology and Otolaryngology and Dermatology (한방안이비인후피부과학회지)

The Society of Korean Medicine Ophthalmology, Otolaryngology & Dermatology (대한한방안이비인후피부과학회)
권호 표지
DOI QR코드

DOI QR Code

Trends of Using UAS7 in Chronic Urticaria Literature and Adherence of UAS7 in a Single Korean Medical Hospital

만성 두드러기의 환자 자기 평가 도구로서 UAS7 사용 현황에 대한 고찰 : 국내외 연구논문 분석 및 일개 한방병원 의무기록을 중심으로

  • Kim, Jae-Ho (Department of Ophthalmology, Otolaryngology and Dermatology of Korean Medicine, Kyung Hee University Hospital at Gangdong) ;
  • Jung, Sol-Mi (Department of Clinical Korean Medicine, Graduate school, Kyung Hee University) ;
  • Choi, In-Hwa (Department of Ophthalmology, Otolaryngology and Dermatology of Korean Medicine, Kyung Hee University Hospital at Gangdong) ;
  • Kim, Min-Hee (Department of Ophthalmology, Otolaryngology and Dermatology of Korean Medicine, Kyung Hee University Hospital at Gangdong) ;
  • Kang, Min-Seo (Department of Ophthalmology, Otolaryngology and Dermatology of Korean Medicine, Kyung Hee University Hospital at Gangdong)
  • 김재호 (강동경희대학교병원 한방안이비인후피부과) ;
  • 정솔미 (경희대학교 일반대학원 임상한의학과) ;
  • 최인화 (강동경희대학교병원 한방안이비인후피부과) ;
  • 김민희 (강동경희대학교병원 한방안이비인후피부과) ;
  • 강민서 (강동경희대학교병원 한방안이비인후피부과)
  • Received : 2021.01.04
  • Accepted : 2021.01.23
  • Published : 2021.02.25
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives : The purpose of this study is to investigate the using trends of UAS7 over the last 5 years to analyze patients using UAS7 in a single Korean medicine hospital and to understand and suggest the actual status of application in clinical research. Methods : PubMed, RISS and OASIS were used to search clinical research papers related to chronic urticaria in the last 5 years. The adherence of UAS7 was assessed based on medical records in a single Korean medical hospital for 4 weeks. Results : Total 536 articles were selected, and 401(74.8%) articles used the assessment tool. UAS7 has been most commonly used assessment tool to evaluate the severity of chronic urticaria and DLQI has been most commonly used to evaluate the quality of life. The usage rate of UAS7 increased from 50% in 2016 to 85% in 2020. There were a total of 10 articles in traditional medicine research, of which 9 assessment tools were used and 4 articles used UAS7. To analyze adherence of UAS7, a total of 15 patients were selected. 6 patients (40%) did not record any value, and only 2 patients(13%) showed more than 80% adherence. Conclusions : UAS7 is most commonly used assessment tool in clinical research currently. However, since patient record adherence tends to be poor, it is needed to find ways increasing the UAS7 record adherence.

Keywords

References

  1. Maurer M, Weller K, Bindslev-Jensen C, Gimenez-Arnau A, Bousquet PJ, Bousquet J, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy 2011;66:317-30. https://doi.org/10.1111/j.1398-9995.2010.02496.x
  2. Lee N, Lee JD, Lee HY, Kang DR, Ye YM. Epidemiology of Chronic Urticaria in Korea Using the Korean Health Insurance Database, 2010-2014. Allergy Asthma Immunol Res. 2017;9(5):438-45. https://doi.org/10.4168/aair.2017.9.5.438
  3. Gaig P, Olona M, Munoz Lejarazu D, Caballero MT, Dominguez FJ, Echechipia S, et al. Epidemiology of urticaria in Spain. J Investig Allergol Clin Immunol 2004;14:214-20.
  4. Kozel MM, Mekkes JR, Bossuyt PM, Bos JD. Natural course of physical and chronic urticaria and angioedema in 220 patients. J Am Acad Dermatol 2001;45:387-91. https://doi.org/10.1067/mjd.2001.116217
  5. Dias GA, Pires GV, Valle SO, Dortas SD Junior, Levy S, Franca AT, et al. Impact of chronic urticaria on the quality of life of patients followed up at a university hospital. An Bras Dermatol. 2016;91(6):754-9. https://doi.org/10.1590/abd1806-4841.20165071
  6. Hiragun M, Hiragun T, Mihara S, Akita T, Tanaka J, Hide M. Prognosis of chronic spontaneous urticaria in 117 patients not controlled by a standard dose of antihistamine. Allergy. 2013;68(2):229-35. https://doi.org/10.1111/all.12078
  7. Van der Valk PG, Moret G, Kiemeney LA. The natural history of chronic urticaria and angioedema in patients visiting a tertiary referral centre. Br J Dermatol. 2002;146:110-3. https://doi.org/10.1046/j.1365-2133.2002.04582.x
  8. Kaplan AP, Greaves M. Pathogenesis of chronic urticaria. Clin Exp Allergy. 2009; 39(6):777-87. https://doi.org/10.1111/j.1365-2222.2009.03256.x
  9. Maurer M, Abuzakouk M, Berard F, Canonica W, Oude Elberink H, Gimenez-Arnau A, et al. The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU. Allergy. 2017;72(12):2005-16. https://doi.org/10.1111/all.13209
  10. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73 (7):1393-414. https://doi.org/10.1111/all.13397
  11. Mlynek A, Zalewska-Janowska A, Martus P, Staubach P, Zuberbier T, Maurer M. How to assess disease activity in patients with chronic urticaria?. Allergy. 2008;63(6): 777-80. https://doi.org/10.1111/j.1398-9995.2008.01726.x
  12. Black N. Patient reported outcome measures could help transform healthcare. BMJ. 2013;346:1-5.
  13. Choi JS, Park YS, Kim JH, Park CS. International Trends on Patient-Reported Outcome Measures for Improving Care Quality and Its Implication for South Korea: Focus on OECD PaRIS. Qual Improv Health Care. 2019;25(1):11-28. https://doi.org/10.14371/QIH.2019.25.1.11
  14. Bae Y, Kang SH, Park JO, Park GH, Choi JH. Serum transglutaminase 2 activity as a potential biomarker of disease severity and response to omalizumab in chronic spontaneous urticaria. Allergol Int. 2020;69(2):304-6. https://doi.org/10.1016/j.alit.2019.10.009
  15. Baiardini I, Braido F, Bindslev-Jensen C, Bousquet PJ, Brzoza Z, Canonica GW et al. Recommendations for assessing patient-reported outcomes and health related quality of life in patients with urticaria: a GA2LEN taskforce position paper. Allergy. 2011;66:840-4. https://doi.org/10.1111/j.1398-9995.2011.02580.x
  16. Baiardini I, Canonica GW, La Grutta S, Braido F. Clinically significant differences in patient-reported outcomes evaluations in chronic spontaneous urticaria. Curr Opin Allergy Clin Immunol. 2020;20(3):261-7. https://doi.org/10.1097/ACI.0000000000000636
  17. Hopkinson K. The role of patient-reported outcomes in the management of chronic spontaneous urticaria. Br J Nurs. 2019; 28(3):144-50. https://doi.org/10.12968/bjon.2019.28.3.144
  18. Moestrup K, Ghazanfar MN, Thomsen SF. Patient-reported outcomes (PROs) in chronic urticaria. Int J Dermatol. 2017;56(12): 1342-8. https://doi.org/10.1111/ijd.13668
  19. Park SY, Kang MS, Kim MH, Kwak JY, Choi IH. A Review of Assessment Tools in Traditional Medicine on the High Frequent Skin Diseases. J Korean Med Ophthalmol Otolaryngol Dermatol. 2018;31(4):31-41. https://doi.org/10.6114/JKOOD.2018.31.4.031
  20. Patruno C, Napolitano M, Ferrucci S, Brambilla L, Hansel K, Corazza M et al. Four-week Urticaria Activity Score-7 as a Useful Patient-reported Outcome to Assess Chronic Spontaneous Urticaria: A Multicentre Study Evaluation of Adherence and Patients' Perspective. Acta Derm Venereol. 2019;99(10):903-4. https://doi.org/10.2340/00015555-3231
  21. Weller K, Church MK, Metz M, Hawro T, Ohanyan T, Staubach P et al. The response to treatment in chronic spontaneous urticaria depends on how it is measured. J Allergy Clin Immunol Pract. 2019;7(6): 2055-6. https://doi.org/10.1016/j.jaip.2019.01.048
  22. Weller K, Groffik A, Church MK, Hawro T, Krause K, Metz M, et al. Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol. 2014;133(5):1365-72. https://doi.org/10.1016/j.jaci.2013.12.1076
  23. Lee JH, Bae YJ, Lee SH, Kim SC, Lee HY, Ban GY, et al. Adaptation and Validation of the Korean Version of the Urticaria Control Test and Its Correlation With Salivary Cortisone. Allergy Asthma Immunol Res. 2019;11(1):55-67. https://doi.org/10.4168/aair.2019.11.1.55
  24. Patruno C, Napolitano M, Ferrucci S, Brambilla L, Hansel K, Corazza M, et al. Four-week Urticaria Activity Score-7 as a Useful Patient-reported Outcome to Assess Chronic Spontaneous Urticaria: A Multicentre Study Evaluation of Adherence and Patients' Perspective. Acta Derm Venereol. 2019;99(10):903-4. https://doi.org/10.2340/00015555-3231
  25. Huber LR, Broel EC, Mitchelides AN, Dmochowski J, Dulin M, Scholes D. Comparison of prospective daily diaries and retrospective recall to measure oral contraceptive adherence. Contraception. 2013;88(4):492-7. https://doi.org/10.1016/j.contraception.2013.02.007
  26. Gimenez-Arnau A, Bartra J, Ferrer M, Jauregui I, Borbujo J, Figueras I, et al. A Specialized Therapeutic Approach to Chronic Urticaria Patient's Refractory to H1-Antihistamines Improves the Burden of the Disease. The Spanish AWARE Experience. 2022;32(3):1-27.
  27. Dekkers C, Alizadeh Aghdam M, de Graaf M, Knulst AC, Meijer Y, van den Reek JMPA, et al. Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients. Pediatr Allergy Immunol. 2021;00:1-7.
  28. Oliver ET, Chichester K, Devine K, Sterba PM, Wegner C, Vonakis BM, et al. Effects of an Oral CRTh2 Antagonist (AZD1981) on Eosinophil Activity and Symptoms in Chronic Spontaneous Urticaria. Int Arch Allergy Immunol. 2019;179(1):21-30. https://doi.org/10.1159/000496162
  29. Ertas R, Ozyurt K, Atasoy M, Hawro T, Maurer M. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change. Allergy. 2018;73(3):705-12. https://doi.org/10.1111/all.13345
  30. Zhang L, Qi R, Yang Y, Gao X, Chen H, Xiao T. Serum miR-125a-5p and CCL17 Upregulated in Chronic Spontaneous Urticaria and Correlated with Treatment Response. Acta Derm Venereol. 2019;99 (6):571-8. https://doi.org/10.2340/00015555-3149
  31. Maurer M, Mathias SD, Crosby RD, Rajput Y, Zazzali JL. Validity and responsiveness of the Urticaria Activity and Impact Measure: A new patient-reported tool. Ann Allergy Asthma Immunol. 2018;120(6):641-7. https://doi.org/10.1016/j.anai.2018.03.012
  32. Kaliyadan F, Ashique KT. Use of Mobile Applications in Dermatology. Indian J Dermatol. 2020;65(5):371-6. https://doi.org/10.4103/ijd.IJD_422_20
  33. Seo JS, Kim YE, Kim AN, Kim IT, Son YH, Jang HC. Study on Compliance of Personal Health Record Application in Patients with Atopic Dermatitis. J Society of Preventive Korean Medicine. 2020;24(2):71-82.
  34. Rijsbergen M, Niemeyer-van der Kolk T, Rijneveld R, Pinckaers JHFM, Meshcheriakov I, Bouwes Bavinck JN, et al. Mobile e-diary application facilitates the monitoring of patient-reported outcomes and a high treatment adherence for clinical trials in dermatology. J Eur Acad Dermatol Venereol. 2020;34(3):633-9. https://doi.org/10.1111/jdv.15872
  35. Hide M, Igarashi A, Yagami A, Chinuki Y, Inomata N, Fukunaga A, et al. Efficacy and safety of omalizumab for the treatment of refractory chronic spontaneous urticaria in Japanese patients: Subgroup analysis of the phase 3 POLARIS study. Allergol Int. 2018;67(2):243-52. https://doi.org/10.1016/j.alit.2017.10.001